Unassociated Document


    Exhibit
      10.1

    


    VioQuest
      Pharmaceuticals, Inc.

    Summary
      of 2006 Management Bonus Plans

    


    Daniel
      Greenleaf

    President
      & Chief Executive Officer

    


    
      	
              Milestone
                

            	 	
              Bonus
                Amount

            	 
	
              Completion
                of financings resulting in gross proceeds of a targeted
                amount

            	 	
              $

            	
              50,000

            	 
	
              Listing
                of common stock on national exchange or Nasdaq

            	 	 	
              50,000

            	 
	
              Initiation
                of 3 clinical trials in the U.S. of Company product candidates under
                Company-sponsored INDs

            	 	 	
              
              

              30,000

            	 
	
              Completion
                of 3 clinical trials in the U.S. of Company product candidates under
                Company-sponsored INDs

            	 	 	
              
              

              30,000

            	 
	
              Acquisition
                of new compound, as approved by the Board

            	 	 	
              30,000

            	 
	
              Chiral
                Quest net loss less than a targeted amount and revenues in excess
                of a
                targeted amount

            	 	 	
              
              

              20,000

            	 
	
              Acceptance
                of NDA filing for review for leishmaniasis indication for
                VQD-001

            	 	 	
              15,000

            	 
	
              Qualitative
                factors based on leadership, teamwork, peer interaction, initiative
                and
                communication

            	 	 	
              
              

              25,000

            	 
	
              TOTAL
                MAXIMUM ELIGIBLE BONUS

            	 	
              $

            	
              250,000

            	 


    

    


    Michael
      Cannarsa, Ph.D.

    General
      Manager, Chiral Quest Inc.

    


    
      	
              Milestone
                

            	 	
              Bonus
                Amount

            	 
	
              2006
                Chiral Quest net loss less than a targeted amount

            	 	
              $

            	
              18,000

            	 
	
              2006
                Chiral Quest revenue at least at a targeted amount and margin equal
                to or
                greater than a targeted percentage 

            	 	 	
              
              

              18,000

            	 
	
              Completion
                of targeted number of strategic transactions

            	 	 	
              7,200

            	 
	
              Qualitative
                factors based on leadership, teamwork, peer interaction, initiative
                and
                communication

            	 	 	
              
              

              4,800

            	 
	
              TOTAL
                MAXIMUM ELIGIBLE BONUS

            	 	
              $

            	
              48,000

            	 


    

    


    Pamela
      Jo Harris, M.D.

    


    
      	
              Milestone
                

            	 	
              Bonus
                Amount

            	 
	
              Initiation
                of Phase I in VQD-001 

            	 	
              $

            	
              1,875

            	 
	
              Completion
                of Phase I in VQD-001

            	 	 	
              4,375

            	 
	
              Initiation
                of Phase I in VQD-002 for solid tumors

            	 	 	
              1,875

            	 
	
              Completion
                of Phase I in VQD-002 for solid tumors

            	 	 	
              4,375

            	 
	
              Initiation
                of Phase I in VQD-002 for hematological malignancies

            	 	 	
              1,875

            	 
	
              Completion
                of Phase I in VQD-002 for hematological malignancies

            	 	 	
              4,375

            	 
	
              NDA
                filing for VQD-001 for leishmaniasis indication

            	 	 	
              3,750

            	 
	
              Qualitative
                factors based on leadership, teamwork, peer interaction, initiative
                and
                communication

            	 	 	
              
              

              2,500

            	 
	
              TOTAL
                MAXIMUM ELIGIBLE BONUS

            	 	
              $

            	
              25,000

            	 


    

    


    


    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Brian
      Lenz

    Chief
      Financial Officer

    


    
      	
              Milestone
                

            	 	
              Bonus
                Amount

            	 
	
              Completion
                of financings resulting in gross proceeds of a targeted
                amount

            	 	
              $

            	
              13,500

            	 
	
              Initiation
                of 3 clinical trials

            	 	 	
              3,825

            	 
	
              Completion
                of non-dilutive financings resulting in proceeds of at least targeted
                amounts

            	 	 	
              
              

              5,625

            	 
	
              Listing
                of common stock on national exchange or Nasdaq

            	 	 	
              9,675

            	 
	
              Chiral
                Quest net loss less than a targeted amount

            	 	 	
              7,875

            	 
	
              Qualitative
                factors based on leadership, teamwork, peer interaction, initiative
                and
                communication

            	 	 	
              
              

              4,500

            	 
	
              TOTAL
                MAXIMUM ELIGIBLE BONUS

            	 	
              $

            	
              45,000

            	 


    

    


    Richard
      Welter, Ph.D.

    Vice
      President of Corporate Business Development

    


    
      	
              Milestone
                

            	 	
              Bonus
                Amount

            	 
	
              Company’s
                acquisition of clinical compound, as approved by the Board (reduced
                by
                half if compound is pre-clinical) 

            	 	
              
              

              $

            	
              
              

              25,000

            	 
	
              Initiation
                of 3 clinical trials

            	 	 	
              5,000

            	 
	
              Completion
                of 3 patient enrollment trials

            	 	 	
              5,000

            	 
	
              Acceptance
                of NDA filing for review for leishmaniasis indication for
                VQD-001

            	 	 	
              10,000

            	 
	
              Qualitative
                factors based on leadership, teamwork, peer interaction, initiative
                and
                communication

            	 	 	
              
              

              5,000

            	 
	
              TOTAL
                MAXIMUM ELIGIBLE BONUS

            	 	
              $

            	
              50,000